The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.
Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.
This bill creates a board, it meaningfully engages a stakeholder council that is appointed in a bipartisan manner and puts ...
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
The program, called 340b, allows eligible safety net providers to purchase drugs at deeply discounted prices, then reinvest ...
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
The Trump administration’s Centers for Medicare and Medicaid Services (CMS) has signaled that it will be revamping the ...
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback